Vaccitech’s Immunotherapy Combo With Opdivo Shows Hepatitis B Promise
Searching For A Functional Cure
The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.
You may also be interested in...
The University of Oxford spin-out is backing its academic partners to succeed against COVID-19 – but must also look to its own commercial future using the same adenovirus platform.
Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.
Novartis is once again looking to be a pioneer in cell and gene therapy, though this time is selecting a potentially less complex administration method.